Novartis moves to block cancer drug generic in US ...

Novartis (NVS) reported $14.05 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 9.2%. EPS of $2.42 for the same period compares to $1.97 a year ago. The ...

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Hikma acquires Novugen’s FDA-approved ANDA for generic Mekinist Trametinib is an orally administered kinase inhibitor medication used to treat certain cancers.

Learn about cost and Mekinist, financial and insurance assistance, ways to lower long-term costs, and more.

Dublin, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The "TAFINLAR + MEKINIST Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report delves deep into the ...

Tafinlar and Mekinist have shown benefits within the oncology field, now being used to treat melanoma and non-small cell lung cancer in patients with BRAF gene mutations. “It has been incredible to ...

Novartis noted that this was sixth FDA approval for Tafinlar + Mekinist, which is used across multiple BRAF V600 solid tumors, including melanoma, thyroid cancer and lung cancer.

This is the first FDA-approved systemic therapy for first-line treatment of pediatric patients with low-grade glioma with a BRAF V600E mutation.

Basel, March 16, 2023 - Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar ® (dabrafenib) + Mekinist ® (trametinib) for the treatment of pediatric ...